Product Description
IASO -782 injection is a fully human anti -CD19 monoclonal antibody, which enhances antibody-dependent cell-mediated cytotoxicity ( Antibody - dependent cell-mediated cytotoxicity , ADCC ). It clears CD19+ B cells and plasma cells through ADCC and antibody- dependent cell-mediated phagocytosis ( Antibody-dependent cellular phagocytosis , ADCP ) , thereby reducing the production of autoantibodies and treating antibody or B cell-mediated autoimmunity disease. At the same time, IASO-782 is a fully human antibody with low potential immunogenicity, and it is not easy to produce anti-drug antibodies after repeated administration. It has potential advantages in the treatment of autoimmune diseases that require long-term repeated administration. (Sourced from: https://cn.iasobio.com/info.php?id=272)
Mechanisms of Action: CD19 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: IASO Biotherapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Anemia, Hemolytic, Autoimmune|Purpura, Thrombocytopenic, Idiopathic|Thrombocytopenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| IASO-782C005 | P1 |
Not yet recruiting |
Thrombocytopenia|Anemia, Hemolytic, Autoimmune|Purpura, Thrombocytopenic, Idiopathic |
2025-11-01 |
12% |
2024-08-02 |
Primary Endpoints|Treatments |
| CTR20232345 | P1 |
Recruiting |
Purpura, Thrombocytopenic, Idiopathic|Thrombocytopenia|Anemia, Hemolytic, Autoimmune |
None |
2025-04-29 |